Beta

Nervgen pharma corp. common stockNGEN.US Overview

US StockHealthcare
(No presentation for NGEN)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

NGEN AI Insights

NGEN Overall Performance

NGEN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NGEN Recent Performance

0.78%

Nervgen pharma corp. common stock

-1.10%

Avg of Sector

-0.49%

S&P500

NGEN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check NGEN's Trend

NGEN Key Information

NGEN Valuation Metrics

NGEN Profile

Price of NGEN

NGEN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NGEN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.38
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
124.74
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.38
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
124.74
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NGEN's latest earnings report released?

    The most recent financial report for Nervgen pharma corp. common stock (NGEN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NGEN's short-term business performance and financial health. For the latest updates on NGEN's earnings releases, visit this page regularly.

  • How much cash does NGEN have?

    At the end of the period, Nervgen pharma corp. common stock (NGEN) held Total Cash and Cash Equivalents of 22.07M, accounting for 0.95 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What are the PEG ratio and PE ratio of NGEN?

    The latest valuation data shows Nervgen pharma corp. common stock (NGEN) has a Price-To-Earnings (PE) ratio of -9.39 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.